 EpidemiologyandInfection
cambridge.org/hygOriginalPaper
*MengyaoJi,LeiYuan,WeiShen,JunweiLv
andLiYongcontributedequallytothispaper.
Citethisarticle:
JiM,YuanL,ShenW,LvJ,Li
Y,LiM,LuX,HuL,DongW(2020).

Characteristicsofdiseaseprogressinpatients

withcoronavirusdisease2019inWuhan,
China.EpidemiologyandInfection
148,e94,
1Œ10.https://doi.org/10.1017/
S0950268820000977
Received:2March2020
Revised:29April2020

Accepted:1May2020
Keywords:
Clinicalstage;COVID-19;Diseaseprogress;
SARS-CoV-2
Authorforcorrespondence:
WeiguoDong,
E-mail:weiguodong_66@163.com
©TheAuthor(s),2020.Publishedby
CambridgeUniversityPress.ThisisanOpen

Accessarticle,distributedunderthetermsof
theCreativeCommonsAttributionlicence
(http://creativecommons.org/licenses/by/4.0/
),whichpermitsunrestrictedre-use,

distribution,andreproductioninanymedium,
providedtheoriginalworkisproperlycited.
Characteristicsofdiseaseprogressinpatients
withcoronavirusdisease2019inWuhan,China
MengyaoJi
1,*,LeiYuan
2,*,WeiShen
3,*,JunweiLv
3,*,YongLi
4,*,MingLi
2,XuefangLu
5,LanhuaHu
5andWeiguoDong
11DepartmentofGastroenterology,RenminHospitalofWuhanUniversity,Wuhan,Hubei,China;
2Departmentof
InformationCenter,RenminHospitalofWuhanUniversity,Wuhan,Hubei,China;
3ShanghaiKeyLaboratoryof
ArtificialIntelligenceforMedicalImageandKnowledgeGraph;
4DepartmentofRadiology,SuiningCentral
Hospital,Suining,Sichuan,Chinaand
5DepartmentofRadiology,RenminHospitalofWuhanUniversity,Wuhan,
Hubei,China
Abstract
Coronavirusdisease2019(COVID-19)patientswereclassifiedintofourclinicalstages
(uncomplicatedillness,mild,severeandcriticalpneumonia)dependingondiseaseseverity.

Weaimtoinvestigatethecorrespondingclinical,radiologicalandlaboratorycharacteristics

betweendifferentclinicalstages.Aretrospective,single-centrestudyof101confirmedpatients

withCOVID-19atRenminHospitalofWuhanUniversityfrom2Januaryto28January2020

wasenrolled;follow-upendpointwason8February2020.Clinicaldatawerecollectedand

comparedduringthecourseofillness.Themedianageofthe101patientswas51.0years

and33.6%weremedicalstaff.Fever(68%),cough(50%)andfatigue(23%)arethemostcom-

monsymptoms.About26%patientsunderwentthemechanicalventilationand98%patients

weretreatedwithantibiotics.Thirty-sevenpercentpatientswerecuredand11died.On

admission,thenumberofpatientswithuncomplicatedillness,mild,severeandcriticalpneu-

moniawere2[2%],86[85%],11[11%]and2[2%].Forty-fourofthe86mildpneumonia

progressedtosevereillnesswithin4days,withninepatientsworsenedduetocriticalpneu-
moniawithin4days.Twoofthe11severepatientsimprovedtomildconditionwhilethree
othersdeteriorated.Significantdifferenceswereobservedamonggroupsofdifferentclinical

stagesinnumbersofinfluencedpulmonarysegments(6
vs.12vs.17,P<0.001).Asignifi-
cantlyupwardtrendwaswitnessedinground-glassopacitiesoverlappedwithstripedshadows

(33%vs.42%vs.55%vs.80%,P<0.001),whilepureground-glassopacitiesgradually
decreasedasdiseaseprogressed(45%
vs.35%vs.24%vs.13%,P<0.001)within12days.
Lymphocytes,prealbuminandalbuminshowedadowntrendasdiseaseprogressedfrom

mildtosevereorcriticalcondition,anuptrendwasfoundinwhitebloodcells,C-reactivepro-

tein,neutrophilsandlactatedehydrogenase.Theproportionsofserumamyloid
A>300mg/l
inmild,severeandcriticalconditionswere18%,46%and71%,respectively.
Introduction
AsthefirstcasesofpneumoniaofunknownoriginwereofficiallyreportedinChinaon8
December2019,thisdiseasehasrapidlyspreadtomanyotherregionswithinChinaand

abroad[
1].Asof13April2020,over1200000confirmedCOVID-19patientshavebeen
documentedworldwide.
Therearemanysimilarities,indicatedbythepublishedliteratures,betweensevereacute
respiratorysyndromecoronavirus2(SARS-CoV-2)andSARSaswellasMERS,suchasthat

theyareallmainlytransmittedthroughrespiratorydroplets,andtheirmostcommonsymp-

tomisfever[
1Œ3].YettheSARS-CoV-2wasalsofoundwithR0[
4].Ithasmoreclinicalsymp-
tomsofdyspnoeawhileheadachesanddiarrhoeaarerare[
5].Astoradiologicalfeatures,
COVID-19usuallyhasabnormalitiesonchestcomputedtomography(CT),ofwhichthe

mosttypicaloneisground-glassopacity,andthelesionsaregenerallymultipleandlocated

intheposteriororperipherallung[
6].PatientsinfectedwithSARS-CoV-2normallydevelop
symptomsin2
7daysafterinfectionwitharapiddiseaseprogress.Theyusuallydieofacute
respiratorydistresssyndrome(ARDS)andmultipleorganfailurecausedbycytokinestorm[
5].DespitemanyreportsonSARS-CoV-2,fewstudiesfocusedondiseaseprogressanditisstill
unclearhowclinical,radiologicalcharacteristicsandlaboratoryindicatorsandtheirdynamic

changesasdiseaseprogressedarerelatedtoprognosis.Inthisstudy,wecomprehensivelycol-

lectedtheclinical,radiologicalcharacteristicsandlaboratoryinformationof101confirmed

COVID-19patientsinRenminHospitalofWuhanUniversityandaimedtoexploretheasso-

ciationbetweenprognosisandthevariationtrendofthoseindicators.
 MethodsThestudywasapprovedbytheEthicsCommitteeoftheWuhan
UniversityRenminHospital(ethicsnumber:V1.0),andwritten

informedconsentwaswaived.Aretrospectivestudywasperformed

on101laboratory-confirmedpatientswithSARS-CoV-2,whowere

randomlyselectedfromalltheconfirmedpatientsfrom2January

2020to28January2020,atWuhanUniversityRenminHospital,

oneofthefirsthospitalsdesignatedbytheChinesegovernment

totreatCOVID-19,usingisolationandairborneprecautions

(fit-testedN95masks)foraerosol-generatingimmediately.The

laboratory-confirmedpatientsweredefinedaspositiveresults

fromanyoneofthefollowingspecimens:respiratorysecretions

obtainedfrombronchialalveolarlavage,trachealaspirate,

nasopharyngealororopharyngealswabs.Clinical,imagingand

laboratorydatawerecollectedandprivacymaskingwasperformed

indataanalysis.Thefollow-upendpointwason8February2020.
Datacollection
Thedemographicandepidemiologicalcharacteristics,laboratory
findingsaswellasclinicaldiagnosisandtreatmentoutcomes

wereextractedfromelectronicmedicalrecords.Severalstandar-

diseddatacollectionformsweredesignedfirstandrelevantdata

werethencorrespondinglyextractedbytwoexperienceddoctors

andathirdseniordoctorwouldperformthefinalreviewto

ensuredataquality.Laboratoryindicatorsofbloodroutinetest,

bloodcoagulationandtheirmedicalreferencerangeswerecol-

lected.ThepresenceofSARS-CoV-2inrespiratoryspecimens

wasdetectedbyreal-timeRT-PCRmethods,issuedbythe

ChineseCDC[
7].Allthethin-layerimageswerecollectedin
theformatofDigitalImagingandCommunicationsin
Medicine(DICOM).Thentheimagingsignsandtheirfeatures
wereextractedusingadouble-blindmethod,bywhichtwointer-

mediateradiologistsinrespiratorymedicine(withmorethan5

years
™experience)wouldreadandreporttheimagesindepend-
entlyandtheirresultswouldfinallybereviewedandconfirmed

byaseniordoctor(engagedinimagingdiagnosisformorethan

15years).Radiologicalfindingssuchaslesions,lesionsize(the

longestdiameterofthelesion)andradiologicalpatternswere

extracted.Inaddition,toevaluatethelesionsizeaccurately,a

diagnosissystemfornovelcoronaviruspneumoniabasedonarti-

ficialintelligence(AI),wasemployedtoanalyseCTimagesusing

CTvaluetomeasurevolumeratioofpneumoniaautomatically,

whichhadbeenusedatthishospitalinearlyJanuary[
8Œ11].Clinicalstaging
TheguidelinesonCOVID-19treatmentissuedbytheNational
HealthCommissionofthePeople
™sRepublicofChinahaveclassi-
fiedpatientsintofourtypes,includinguncomplicatedillness,mild,

severeandcriticalpneumonia[
12].Patientswithuncomplicated
illnesshavemildclinicalsymptomsbutnosignsofpneumonia

onchestimages,whilemildpneumoniahasfeverandrespiratory

symptomsaswellaspneumonitissignsonradiographs.Severe

patientshaveatleastoneofthefollowing:(1)respiratorydistress,

respiratoryrate(RR)
30breaths/min;(2)fingeroxygensatur-
ation
93%inastateofrest;(3)partialpressureofoxygen
(PaO
2)/fractionofinspiredoxygen(FiO
2)300mmHg.Critical
pneumoniahasoneofrespiratoryfailurewithmechanicalventila-

tionrequired,shock,otherorgansfailurerequiredICUmonitor-

ing.Itshouldbenotedthateachpatientmayhavemultiple
clinicalstagesasthediseaseprogressed.Werecordedalltheclinical
classificationsforeveryselectedpatientandthetimeatwhichthe

classificationbeganorchangeofclassificationoccurred.Thetime

(±2days)wasthenusedtomatchtheirlatestimagingandlabora-

toryinformationforeachclinicalstageofthepatients.
Statisticalanalysis
Clinicalcharacteristicsweredescribedviameansandstandard
deviations(fornormallydistributedvariables)orinterquartile

range(Median(IQR))(fornotnormallydistributedvariables)or

frequencyandpercentages(forcategoricalvariables),andtheir

differenceswerethencorrespondinglycomparedby
ttest,
MannWhitney
Utest(orKruskal
Wallis
Htest),Chi-square
test(orFisher
™sexactprobability),respectively.Cochran
Armitagetrendtestwasfurtherusedtocheckwhetheranupward
ordownwardtrendexistsinordinaryvariables.A
P-value<0.05was
consideredstatisticallysignificant.Allanalyseswereperformed

usingSAS9.4(SASInstitute,Cary,NC,2017)whilegraphswere

plottedbyR-3.6.0.
Results
Demographicandclinicalcharacteristicsofstudyparticipants

Themedianageofthe101patientswas51.0years(IQR37.0
Œ61.0),and53(52%)werefemale.Amongthem,34(34%)were

medicalstaffand47(47%)hadsuspectednosocomialinfections.

Morethanhalfofthepatients(51%)hadcoexistingdisorders,

whichmainlywerehypertension(20%),cardiovascularorcere-

brovasculardisease(14%),diabetes(13%)andmalignanttumours

(12%).Noneofthe101patientshadahistoryofexposuretothe

WuhanHuananseafoodmarket.Thecommonsymptomsinclude

fever(68%),cough(50%),fatigue(23%),myalgia(16%)anddys-
pnoea(14%).Mechanicalventilation,primarilynasalcannula/
oxygenmask(20patients,20%),wasusedin26patients(26%).

Almostallthepatients(98%)weretreatedwithantibiotics.

Whileinterferon,antiviral,gammaglobulinandthymosinther-

apywereinitiatedin40(40%),85(84%),65(64%)and10

(10%)patients,respectively.Themediantimefromtheinitial

symptom,hospitaladmissiontothelaboratory-confirmeddiag-

nosiswere7.0days(IQR:5.0
Œ13.0)and4.0days(IQR:2.0
Œ7.0).Overall,theperson-timesofuncomplicatedillness,mild,severe

andcriticalpneumoniawastherewere1,88,55and14during

courseofillness,respectively.Asof8February2020,morethan

one-third(37,37%)werecuredanddischarged,onehalf(53,

52%)remainedhospitalised,respectively,while11(11%)patients

diedunfortunately,asshownin
Table1
.Figure1
depictedtheflowchartofdiseaseprogressof101
patients.Onadmission,1,86,11and2ofthe101patientswerediag-

nosedasuncomplicatedillness,mild,severe,andcriticalpneumo-

nia,respectively.Additionally,onewomandidnothaveaclinical

stageduetopregnancy.Duringthecourseofillness,44(51%)

mildpatientsprogressedtosevereconditionwithinamedian

timeof4days(IQR:1
Œ7),amongwhichninecases(10%)further
worsenedtocriticalpneumoniawithin4days(IQR:3
Œ8)from
severeillness.Whiletwoofthe11severepatientsimprovedto

mildcondition,threeothersdeterioratedtocriticalcondition.
Radiologicalcharacteristicsstratifiedbyclinicalstages
Radiologicalabnormalitieswerefoundin121CTscans.
Themajorityofabnormalitieswerepresentedwithmultiple
2MengyaoJi
etal.
 Table1.
Clinicalcharacteristicsof101patientswithCOVID-19
VariablesTotal(
N=101)Non-medicalstaff(
N=67)Medicalstaff(
N=34)
Pvalue
Age,years51.0(37.0
Œ61.0)57.0(44.0
Œ64.0)34.0(30.0
Œ42.0)<0.001***
Sex
0.44Male48(48%)30(45%)18(53%)

Female53(52%)37(55%)16(47%)
Suspectednosocomialinfection47(47%)13(19%)34(100%)<0.001***
Coexistingdisorders52(51%)48(72%)4(12%)<0.001***

Diabetes13(13%)13(19%)0(0%)0.004
a**Hypertension20(20%)19(28%)1(3%)0.002**

Cardiovascularorcerebrovasculardisease14(14%)14(21%)0(0%)0.002
a**Chronicobstructivepulmonarydisease2(2%)2(3%)0(0%)0.55
aMalignanttumours12(12%)12(18%)0(0%)0.007
a**Chronicliverdisease6(6%)5(7%)1(3%)0.66
aChronicrenaldisease4(4%)4(6%)0(0%)0.30
aHistoryofexposuretotheWuhanseafoodmarket0(0%)0(0%)0(0%)NA

Smoking5(5%)4(6%)1(3%)0.66
aPregnancy1(1%)0(0%)1(3%)0.34
aExistinginitialsymptoms90(89%)58(87%)32(94%)0.33
aFever69(68%)45(67%)24(71%)0.73

Cough50(50%)27(40%)23(68%)0.009**

Expectoration20(20%)14(20%)6(18%)0.70

Fatigue23(23%)14(21%)9(26%)0.53
Chestdistress13(13%)9(13%)4(12%)1
aVertigo4(4%)4(6%)0(0%)0.30
aMyalgia16(16%)7(10%)9(26%)0.037*
Headache6(6%)3(4%)3(9%)0.40
aDiarrhoea1(1%)0(0%)1(3%)0.34
aDyspnoea14(14%)14(21%)6(18%)0.002
a**Nausea3(3%)3(4%)0(0%)0.55
aTimefrominitialsymptomstodiagnosis7.0(5
Œ13)10.0(6
Œ15)5.5(2
Œ7)<0.001***
Timefromadmissiontodiagnosis4.0(2
Œ7)6.0(3
Œ10)1.5(0
Œ3)<0.001***
Physicalexaminationonadmission
Temperature,°C36.8(36.5
Œ37.2)36.8(36.5
Œ37.5)36.8(36.6
Œ37)0.64
Pulse,mean(
S.D.)84.0(13.0)87.7(12.6)76.9(10.5)<0.001***
Respiratoryrate19.0(18
Œ20)20.0(19
Œ20)19.0(18
Œ19)<0.001***
Systolicbloodpressure,mmHg125.0(117
Œ133)125.0(113
Œ138)123.0(118
Œ125)0.30
Diastolicbloodpressure,mmHg75.0(69
Œ81)76.0(69
Œ83)75.0(69
Œ78)0.220
Mechanicalventilation26(26%)24(36%)2(6%)0.001**

Ventilatorytype
0.600
aNasalcannula/oxygenmask20(80%)18(78%)2(100%)
Non-invasiveventilationorhigh-
ownasalcannula3(3%)3(13%)0(0%)
Invasivemechanicalventilation2(2%)2(9%)0(0%)
DrugsGlucocorticoid66(65%)43(64%)23(68%)0.73
(Continued
)EpidemiologyandInfection
3 lesions(105,87%),bilaterallungsaffected(97,80%).Themost
commonlesionslocatedintheposteriorbasalsegmentofthe

leftlowerlobe(LLL)(72%),followedbytheposteriorbasal

segmentoftherightlowerlobe(RLL)(67%),whiletheanterior

basalsegmentoftheRLLandtheanteriorsegmentoftheleft

upperlobe(LUL)wereaffectedtheleast(36%and40%).The

mostcommonpatternsonchestCTwerepureground-glass

opacity((44,36%),
Fig.2a
)andground-glassopacitiesoverlapped
withstripedshadows((48,40%),
Fig.2b
).Inaddition,18cases
showedpulmonaryconsolidation(
Fig.2c
),fourshowedreticular
patterns(
Fig.2d
)andthreemixedpatterns(
Fig.2e
).Mostofthe
cases(65%)wereaccompaniedbyperipheralvesselsthickening,

followedbyairbronchogram(44%),mosaicsigns(14%),

pleuraleffusion(14%)andhalosigns(13%).Significant

differenceswereobservedinbilateral/left/rightlungsofbeing

influenced(
P=0.07),multipleorsinglelesions(
P=0.033),
lesionsize(
P=0.003),numbersofinfluencedpulmonary
segments(
P<0.001)andnumbersofpulmonarysegmentswith
stripedshadows(
P=0.017)amonggroupswithdifferentclinical
stages(
Table2
).Table1.
(Continued.
)VariablesTotal(
N=101)Non-medicalstaff(
N=67)Medicalstaff(
N=34)
Pvalue
Antibiotic99(98%)66(99%)33(97%)1
aInterferon40(40%)10(15%)30(88%)<0.001***
Antiviraldrug85(84%)54(81%)31(91%)0.17

Gammaglobulin65(64%)43(64%)22(65%)0.96

Thymosin10(10%)7(10%)3(9%)1
aClinicalstages
Uncomplicatedillness1(1%)0(0%)1(3%)0.34
aMild88(87%)57(85%)31(91%)0.53
aSevere55(54%)45(67%)10(29%)<0.001***
Critical14(14%)14(21%)0(0%)0.002
a**Outcome0.044*
Death11(11%)11(16%)0(0)
Hospitalisation53(52%)33(49%)20(59%)
Cured37(37%)23(34%)14(41%)
Note:Dataarepresentedasmedians(interquartileranges,IQR)and
N(%).aPvaluewascalculatedusingFisher
™sexactprobabilityinsteadof
2test.
*Pvalue<0.05,**
Pvalue<0.01,***
Pvalue<0.001.
Fig.1.
Flowchartofdiseaseprogressionof101patients.
4MengyaoJi
etal.
 Radiologicalfindingsasdiseaseprogressed
Theaverageintervalbetweenthesecond,thirdandfourthCT
examinationsandthefirsttimewas4,7and10days,respectively.

Besides,singlelesiongraduallydevelopedtomultipleonesinthe

diseaseprogression,withanincreasingtrend(
P=0.05)inmedian
affectedpulmonarysegments(7.0,9.0,10.5and12.0)(TableS1in

SupplementaryAppendix).Intermsofradiologicalpatterns,an

upwardtrendwasobservedinthenumbersofground-glassopa-

citiesoverlappedwithstripedshadows(33%,42%,55%and80%),

asshowninTableS1.Correspondingly,thepercentageofpure

ground-glassopacitiespresentedwithadecreasingtrend(45%,

35%,24%and13%)forthefirsttimeCTscanstothefourth

timeCTscanswithin12daysasthediseaseprogressed.

Representativeradiologicalfindingsduringcourseofillness

couldbefoundinFigureS1.
Laboratoryparametersstratifiedbyclinicalstages
Significantdifferenceswereobservedamonggroupsofdifferent
clinicalstagesinlactatedehydrogenase(
P=0.001),bloodurea
(P=0.03),procalcitonin(
P=0.002)andD-dimer(
P<0.001),
prothrombintime(
P=0.003),lymphocytecount(
P=0.001),
whitebloodcells(
P=0.006),neutrophilcount(
P=0.001),
lymphocyteratio(
P<0.001),C-reactiveprotein(
P<0.001),albu-
min(
P<0.001),prealbumin(
P<0.001)andserumamyloid(
P<0.001)(
Table3
).Asillustratedin
Figure3
,lymphocytesprealbu-
minandalbumindecreasedasdiseaseprogressedwhilean

upwardtrendwaswitnessedinwhitebloodcells,C-reactivepro-

tein,neutrophilsandlactatedehydrogenasedecreaseovertime.
ThemostpredominantspectrumofserumamyloidAwas5
300,>300and>300mg/linmild(60%),severe(46%),critical
(71%)conditions,respectively.
Discussion
Thisretrospectivestudy,toourbestknowledge,isthefirstreportto
thediseaseprogressionofpatientswithSARA-CoV-2.Asof28

January2020,atotalof101confirmedCOVID-19patientswere

enrolledinthisstudy,andclassifiedintofourdifferentgroups

(uncomplicatedillness,mild,severeandcriticalpneumonia)

accordingtothediseaseseverity.Amongthesepatients,86and

11patientswerediagnosedasmildandseverepneumonia,aswell

asoneuncomplicatedillnessandtwocriticalpneumoniaonadmis-

sion.Themedianageofthesepatientswas51.0years(IQR37.0
Œ61.0),34%weremedicalstaffand47%hassuspectednosocomial

infections,thisiscausedbytherapidperson-to-persontransmis-

sionofCOVID-19withlesspersonalprotection.Fever(68%),

cough(50%),fatigue(23%)andmyalgia(16%)arethemostsymp-

tomsonadmission.Fifty-onepercentpatientshavecomplications,

withhypertension(20%),cardiovascularorcerebrovasculardisease

(14%)anddiabetes(12%),respectively.Themostcommonpatterns

onchestCTwerepureground-glassopacity(36%)andground-

glassopacitiesoverlappedwithstripedshadows(40%).About

26%patientsunderwentthemechanicalventilation.Thesefindings

conformwiththepreviousstudyofCOVID-19inWuhan,China[
5,13].Asof8February2020,morethanone-third(37,37%)of
patientswerecuredanddischarged,ahalf(53,52%)werestillhos-

pitalised,while11(11%)patientsdiedunfortunately.Themedian

timefrominitialsymptomstodiagnosiswas7days(IQR5
Œ13),Fig.2.
TypicalradiologicalpatternsonchestCTimages.(a)pureground-glassopacity;(b)round-glassopacitiesoverlappedwithstripedshadows;(c)pu
lmonaryconsolidation;(d)reticularpatterns;(e)mixedpatternsand(f)others.TheillustrationdepictedasecondarytuberculosiscaseinfectedwithSA
RS-CoV-2.
EpidemiologyandInfection
5 Table2.
Radiologicalfindingsstratifiedbyclinicalstages
VariablesOverall(
N=121)Mild(
N=70)Severe(
N=42)Critical(
N=9)
PvalueRadiologicalabnormalities
0.75aGround-glassopacitiesoverlappedwithstriped
shadows48(40%)31(44%)14(33%)3(33%)
Pureground-glassopacity44(36%)25(36%)15(36%)4(44%)
Mixedpatterns3(2%)1(1%)2(5%)0(0)

Consolidation18(15%)10(14%)7(17%)1(11%)

Reticularpatterns4(3%)2(3%)2(5%)0(0%)
Others4(3%)1(1%)2(5%)1(11%)
Bilaterallungsaffected
0.07aBilaterallungs97(80%)50(71%)38(91%)9(100%)
Rightlung12(10%)11(16%)1(2%)0(0%)

Leftlung12(10%)9(13%)3(7%)0(0%)
Singleormultiplelesions
a0.033*Singlelesion16(13%)14(20%)2(5%)0(0%)

Multiplelesions105(87%)56(80%)40(95%)9(100%)
Lesionsize
0.003a**<1cm4(3%)3(4%)1(2%)0(0%)

1Œ3cm35(29%)23(33%)11(26%)1(11%)
3cm-50%lunglobe66(55%)42(60%)20(48%)4(44%)
>50%lunglobe16(13%)2(3%)10(24%)4(44%)
AI-basedvolumeratioofpneumonia
7005000.19(0.11
Œ0.29)0.16(0.10
Œ0.26)0.20(0.14
Œ0.35)0.49(0.32
Œ0.54)0.002
6005000.12(0.07
Œ0.20)0.09(0.07
Œ0.17)0.14(0.09
Œ0.25)0.32(0.20
Œ0.41)0.002
5002000.05(0.03
Œ0.09)0.04(0.03
Œ0.08)0.07(0.04
Œ0.11)0.14(0.09
Œ0.20)0.003
Numberofaffectedlungsegments9.5(3
Œ14)6.0(2
Œ12)12.0(6
Œ15)17.0(10
Œ18)<0.001***
Airbronchogram53(44%)25(36%)21(50%)7(78%)0.034*

Vesselthickening79(65%)42(60%)30(71%)7(78%)0.34

Halosigns16(13%)8(11%)7(17%)1(11%)0.69

Reversehalosigns5(4%)2(3%)3(7%)0(0%)0.57
aMosaicsigns17(14%)5(7%)9(21%)3(33%)0.024*
Emphysema16(13%)7(10%)7(17%)2(22%)0.42
Pleuraleffusion17(14%)5(7%)10(24%)2(22%)0.037*

Stripedshadows72(60%)40(57%)27(64%)5(56%)0.73

Numberoflungsegmentswithstripedshadows7.0(3
Œ12)4.0(2
Œ8)9.5(5
Œ13)9.5(8
Œ13.5)0.017*
Numberoflungsegmentswithabnormalities
ApicalsegmentofRULL59(49%)27(46%)26(44%)6(10%)0.028
a*PosteriorsegmentofRULL66(55%)31(47%)28(42%)7(11%)0.029
a*AnteriorsegmentofRULL46(38%)21(46%)20(43%)5(11%)0.094

OutersegmentofRMLL62(51%)31(50%)24(39%)7(11%)0.12
aInnersegmentofRMLL50(41%)24(48%)21(42%)5(10%)0.18

DorsalsegmentofRLLL69(57%)35(50%)29(42%)5(7%)0.14
BasalsegmentofRLLL57(47%)23(40%)26(46%)8(14%)<0.001
a***AnteriorbasalsegmentofRLLL43(36%)15(35%)22(51%)6(14%)<0.001***
(Continued
)6MengyaoJi
etal.
 Table2.
(Continued.
)VariablesOverall(
N=121)Mild(
N=70)Severe(
N=42)Critical(
N=9)
PvalueOuterbasalsegmentofRLLL74(61%)41(55%)27(36%)6(8%)0.78
PosteriorbasalsegmentofRLLL83(69%)44(53%)31(37%)8(10%)0.19
PosteriorapicalsegmentofLULL49(41%)23(47%)21(43%)5(10%)0.13

AnteriorsegmentofLULL48(40%)23(48%)20(42%)5(10%)0.18

UpperlingualsegmentofLULL50(41%)21(42%)22(44%)7(14%)0.005**

SublingualsegmentofLULL62(51%)27(44%)28(45%)7(11%)0.004
a**DorsalsegmentofLLLL68(56%)31(46%)31(46%)6(9%)0.008***
AnteriormedialbasalsegmentofLLLL61(50%)29(48%)25(41%)7(11%)0.045
a*OuterbasalsegmentofLLLL70(58%)34(49%)29(41%)7(10%)0.047*

PosteriorbasalsegmentofLLLL87(72%)42(48%)37(43%)8(9%)0.003**
RULL,rightupperlunglobe;RLLL,rightlowerlunglobe;RMLL,rightmiddlelunglobe;LULL,leftupperlunglobe;LLLL,leftlowerlunglobe.
Note:Dataarepresentedasmedians(interquartileranges,IQR)and
N(%).aPvaluewascalculatedusingFisher
™sexactprobabilityinsteadof
2test.
*Pvalue<0.05,**
Pvalue<0.01,***
Pvalue<0.001.
Table3.
Laboratoryparametersstratifiedbyclinicalstages
ParametersTotal
Patients(
N=101)
P-valueMild(
N=88)Severe(
N=55)Critical(
N=14)
CreatinekinaseU/l68.5(41.2
Œ100.5)73.0(48.5
Œ97.0)64.0(33.0
Œ103.0)53.5(37.3
Œ93.3)0.70
LactatedehydrogenaseU/l237.0(191.5
Œ302.5)213.0(179.5
Œ271.0)257.0(217.0
Œ319.0)350.0(248.0
Œ494.0)0.001**
ALTU/l21.0(14.0
Œ33.0)19.5(13.0
Œ31.5)21.5(15.3
Œ38.5)25.0(19.8
Œ30.3)0.42
ASTU/l24.0(19.0
Œ32.3)24.0(19.0
Œ30.0)24.5(19.0
Œ32.0)35.0(21.8
Œ42.8)0.16
Totalbilirubin
mol/l8.9(7.4
Œ12.8)8.6(7.4
Œ12.8)8.7(7.3
Œ12.8)11.0(8.8
Œ12.5)0.78
Creatininemmol/l59.0(50.0
Œ81.3)60.5(51.0
Œ77.8)56.0(48.0
Œ84.5)62.0(50.5
Œ112.3)0.71
Bloodureammol/l4.5(3.7
Œ6.0)4.3(3.7
Œ5.1)4.8(3.1
Œ6.7)6.4(5.1
Œ10.2)0.03*
Procalcitoninng/ml0.06(0.03
Œ0.12)0.04(0.03
Œ0.09)0.08(0.04
Œ0.13)0.17(0.09
Œ1.26)0.002**
D-dimermg/l0.5(0.2
Œ1.3)0.4(0.2
Œ0.7)0.6(0.3
Œ1.2)1.7(1.0
Œ3.4)<0.001***
Prothrombintimesec11.3(10.9
Œ12.0)11.2(10.7
Œ11.8)11.3(10.9
Œ11.8)12.1(11.7
Œ12.9)0.003
Plateletcount10
9/l163.5(122.3
Œ213.8)161(128.0
Œ195.0)180.0(122.5
Œ237.5)165.5(107.5
Œ229.0)0.54
Monocytecount10
9/l0.4(0.3
Œ0.6)0.5(0.3
Œ0.6)0.4(0.2
Œ0.5)0.3(0.1
Œ0.6)0.12
Lymphocytecount10
9/l1.0(0.7
Œ1.5)1.15(0.8
Œ1.5)0.92(0.6
Œ1.4)0.59(0.5
Œ0.9)0.001***
Whitebloodcells10
9/l5.2(3.9
Œ7.1)4.8(3.8
Œ6.4)5.2(4.0
Œ7.3)9.8(6.3
Œ11.7)0.006**
Neutrophilcount10
9/l3.3(2.4
Œ5.2)3.2(2.2
Œ4.2)3.3(2.5
Œ6.1)8.5(4.2
Œ10.6)0.001**
Lymphocyteratio%21.7(12.3
Œ30.5)24.6(15.9
Œ32.4)18.0(8.7
Œ28.9)5.5(4.3
Œ14.9)<0.001***
CRPmg/l17.2(5.9
Œ56.0)12.6(3.9
Œ39.6)24.7(12.0
Œ59.8)91.6(49.8
Œ124.6)<0.001***
Albuming/l37.0(33.7
Œ40.8)39.6(36.5
Œ42.1)34.7(32.6
Œ37.8)31.9(29.9
Œ36.0)<0.001***
Directbilirubin
mol/l3.4(2.5
Œ4.8)3.3(2.5
Œ4.3)3.3(2.6
Œ5.0)4.2(3.3
Œ5.5)0.36
Globuling/l23.4(21.6
Œ26.8)23.3(21.2
Œ25.5)24.09(21.8
Œ27.2)26.8(24.2
Œ28.7)0.06
Prealbuminmg/l130.8(95.1
Œ189.1)149.6(107.5
Œ200.8)121.59(92.22
Œ174.7)89.9(57.3
Œ94.3)<0.001***
SerumamyloidAmg/l
<0.001***<5.03319(22%)12(22%)2(14%)

5.0Œ300.07353(60%)18(33%)2(14%)
>300.05116(18%)25(46%)10(71%)
Note:Dataarepresentedasmedians(interquartileranges,IQR)and
N(%).*Pvalue<0.05,**
Pvalue<0.01,***
Pvalue<0.001.
EpidemiologyandInfection
7 aswellas4.0days(IQR2
Œ7)formediantimefromadmissionto
diagnosis.Thisfindingfurtherconfirmstheviewpointthatthe
mediantimefromonsettoadmissionwas7daysbyHuang
etal
.[5].However,themediantimefrominitialsymptomstodiagnosis
wasshortenedgreatlyduringJanuary(FigureS2),thisisduetothe

substantialsuppliesofSARS-Cov-2detectionkit.Thissharpdown-

trendcouldalsobewitnessedformediantimefromadmissionto

diagnosis.Notable,themajority(72%)ofthenon-medical-staffpatients
hadcomplications,whichprimarilywerecardiovasculardiseases

anddiabetes.ThisproportionwashigherthanSARSbutclose

toMERS[
14],suggestingthatpatientswithpre-existingcondi-
tionsshouldgetwell-preparedforthepreventionof

SARS-CoV-2.Onadmission,mostpatientshadfever(68%),the

mostcommonsymptomofthediseaseinthestudy.

Importantly,asignificantproportionofpatientswithoutfever

inanearlystage,andweremorevulnerabletobeignored,indicat-

ingthatmoreattentionshouldbegiventopatientswithoutfever

whenscreeninganddiagnosingCOVID-19.
Additionally,86ofthe101patientswerediagnosedwithmild
pneumoniaonadmission,42ofthe86patientsmaintainedor

improved.Meanwhile,19of42getcuredinashortperiodand

nodeathoccurred.While,44ofthe86mildpneumoniapatients

progressedtosevereconditionwithin4days,amongwhich13

werecuredand11died.Thissuggestedthatweshouldpay

moreattentiontothediseaseatanearlystage,ratherthanneglect-

ingthemildillness.Besides,wecouldseethatCOVID-19pro-

gressesrapidlywithin4daysfrommild-to-severecondition,

furtherillustratedbyvariationsinradiologicalcharacteristics

overtimeinthisstudy.Indeed,itissignificantlycrucialto

speedupthediagnosisprocessofsuspectedcasesandmake

sureallpotentialpatientsareabletogetaccesstohospitalsfor

observationandtreatmentatanearlystage.Furthermore,patients

withcomplicationscouldhighlydevelopsevereandcriticalillness
asdiseaseprogressed.Alsowhetherornothavingdyspnoeaasini-
tialsymptomsandtherespiratoryfrequencyinphysicalexamin-
ationonadmissionwerebothsignificantlydifferentamong

groupsofdifferentclinicalstages(higherprobabilityobserved

insevereorcriticalstagethanthemildone),suggestingthatatten-

tionshouldbepaidtothepatient
™sunderlyingdiseaseandfirst
symptomswhentreatingCOVID-19[
8,15Œ17].Moreover,mostpatientspresentedwithpatchy,lumpyorseg-
mentalground-glassshadowsinthesubpleuralareainanearly

stage.Also,themostcommonlesionswereontheposteriorand

lateralsidesofthelowerpulmonarylobe.Yetitwaslightinthe

shadowsofinfiltrationofinflammationinlunglobeatthebegin-

ning,mainlyrelatedtoitspathologicalchanges,stillsuggesting

thattheSARS-CoV-2alreadyaffectedthelungbeforesymptoms

werebeingrecognised.Asthediseaseprogressed,anupward

trendwasobservedinthenumbersofground-glassopacitiesover-

lappedwithstripedshadows,ofaffectedpulmonarysegments,

illustratingthatpulmonaryfibrosisbecamemoresevereandto

someextentfurthersuggestingthatpatientsareatriskofirrevers-

ibledamagetolungfunctioninthefuture,whichmayfurtherlead

tofunctionaldisabilityandaffectthequalityoflife.Suchsequelae

occurredinbothpatientsinfectedwithSARSorMERS[
11,18].Hence,addingsupportivetreatmenttothetherapeuticregimen

shouldbetakenintoconsiderationtoimprovepatient
™simmunity,
toweakenthedamagestothelungscausedbyviralpneumonia

andtoreducetheriskofsequelae.Inaddition,nosignificantdif-

ferencewasshownintypicalradiologicalpatternsamonggroups

ofdifferentclinicalstagesbutmosaicsignsandpleuraleffusion,

whichmightrelatetoprognosis.Meanwhile,AI-baseddiagnosis

systemshowedsimilarresultsinassessmentoflesionssizeas

whatwasevaluatedbytheradiologists.Itisalsoworthmention-

ingthatsuchAIsystemgreatlyimproveddiagnosticefficiencyof

COVID-19,alleviatingthesurgeindemandofradiologistswhen

thevirusisstalkingChina.
Fig.3.
Laboratoryparametersstratifiedbyclinicalstages.
8MengyaoJi
etal.
 Inthisstudy,significantdifferenceswerefoundinlactate
dehydrogenase,D-dimer,prothrombin,lymphocytecount,white

bloodcellcount,neutrophilcount,C-reactiveprotein,albumin

andserumamyloidAasthediseaseprogressed.Someofthose

indicatorswereinconsistentwithpreviousstudies[
13].Inadd-
ition,weobservedthattheamountofalbuminandprealbumin

incriticallyorseverelyillpatientsweresignificantlylowerthan

thoseofmildones.Suchdifferencesmightrelatetothecytokine

stormcausedbythevirusatthelatestageofthediseaseandother

factors,suchassubsequenthypoxia,gastrointestinaldysfunction,

endocrineandmetabolicdisorders,insufficientnutritionintake

andtheuseofventilatorwithpositivepressure,andincreased

energyconsumptioninthebody.Eventually,malnutrition

wouldbecausedoraggravated.Asanegativeacutephase

responseproteinandakindofsubstanceinnon-specifichost

defense,prealbumincanclearthetoxicmetabolitesreleasedin

thecirculationduringtheinfectionprocess,andthereforeits

amountreducedinbloodasitwasgraduallyconsumed.This

remindsustoprovidenutritionsupportforthesekindofpatients

[19].Meanwhile,wefoundthatsomeinflammationindicators,
suchasC-reactiveprotein,andserumamyloidA,increasedin

theearlystageofthedisease,buthigheramountsofthemwere

observedinsevereandcriticalpatientsthanthatofmildcases.

Thismightindicatethepatientswereinthestateofacutestress

withelevatedserumamyloidAandC-reactiveprotein,which

areabletobindvariousmicroorganisms
™polysaccharidesandtis-
suecells
™phospholipidsandnucleicacidstoactivatetheimmune
system,improvingimmunityandmediatinginflammatory
responses.
Nodifferenceontreatmenteffectofvariousdrugswas
observedforpatientswithdifferentdiseaseprogressionstates;it

mightbeduetothefactthatthereisnospecifictreatmentguide-

lineforpatientswithnovelcoronaviruspneumoniaatdifferent

states,whichmightbethemaincausesforthedeathofsevere

andcriticalpatients.Inaddition,theevidencescollectedinthis

studycannotconfirmwhichtreatmentcanobviouslycontrol

thediseaseprogressionamongcurrentclinicaltreatmentregi-

mens.Therefore,pro-activeactionsshouldbetakentoaccelerate

theclinicaltrialforpotentialeffectdrugs,suchasRemdesivir,and

variousdrugcombinations[
9,20];meanwhile,moreexisting
drugsonthemarket,whichcanenhanceimmuneresponse,

reduceimmunopathologyandpreventorsuppressARDS,such

asmetformin,glitazone,sartans,atorvastinandrelativenutri-

tionalsupplementsandbiologics,mightbeeffectivetreatment

optionsforthisdisease[
4,21Œ23].Thisstudyhasseverallimitations.Firstly,only48ofthe101
patientsincludedinthestudycurrentlyhaveanendpoint,and

theothersarestillundertreatment,thereforenoindicatorsrelated

toprognosiscouldbeselectedandfurtherexplored.Secondly,

despitethefactthatwebelievedthatcellularandhumoral

immunityplayanimportantroleinthediseaseprocess,itwas

notusedasaroutinetest,aswedidnotfullyunderstandthedis-

easeatanearlystage,makingtheseimportantindicatorsimpos-

sibletoanalyse.Nevertheless,weweretocollectrelevant

informationforfurtheranalysis.Thirdly,datasamplesarelimited

becauseweneedtocontinuallyandactivelyfightandtreat

SARS-CoV-2.
Conclusion
TheCOVID-2019progressesrapidlyandearlyinterventionand
treatmentarecriticallycrucialforpatients
™prognosis.
Radiologicalpatternsandlaboratoryparameterscantimelyreflect
disease™sprogression,providingusefulhelpfordisease
™sdiagnosis
andtreatment.
Supplementarymaterial.
Thesupplementarymaterialforthisarticlecan
befoundat
https://doi.org/10.1017/S0950268820000977
.Authorcontributions.
Ji,MY,Yuan,L,Shen,W,Lv,JWandShi,Lhaddevisedtheidea,designedthestudyand
hadfullaccesstoalldataduringthestudyandhavetakentheresponsibilityfortheinteg-
rityofthedataandtheaccuracyofthedataanalysis.Dong,WGandYuan,Lcontributed
towritingthereport.Ji,MYcontributedtocriticalrevisionofthereport.Yuan,LandLi,

Mcontributedtocollectthedata.Li,Y,Hu,LHandLu,XFcontributedtoreadtheCT

pictures.Xie,WJandShen,Wcontributedtothestatisticalanalysis.Allauthorscontrib-
utedtodataacquisition,dataanalysisordatainterpretation,andreviewedandapproved
thefinalversion.
Financialsupport.
NationalNaturalScienceFoundationofChina
(81901817);NaturalScienceFoundationofHubeiProvince(2018CFB136);

InnovationSeedFundingofWuhanUniversity(TFZZ2018020).
Conflictsofinterest.
Noconflictofinterest.
References
1.LuHZ,StrattonCWandTangYW
(2020)Outbreakofpneumoniaof
unknownetiologyinWuhan,China:themysteryandthemiracle.
JournalofMedicalVirology
92,401
Œ402.2.ZumlaA
etal
.(2019)VaccineagainstMiddleEastrespiratorysyndrome
coronavirus.
TheLancetInfectiousDiseases
19,1054
Œ1055.3.ChenN
etal
.(2020)Epidemiologicalandclinicalcharacteristicsof99
casesof2019novelcoronaviruspneumoniainWuhan,China:adescrip-
tivestudy.
Lancet(London,England)
395,507
Œ513.4.LiQ
etal
.(2020)EarlytransmissiondynamicsinWuhan,China,ofnovel
coronavirus-infectedpneumonia.
TheNewEnglandJournalofMedicine
382,1199
Œ1207.5.HuangC
etal
.(2020)Clinicalfeaturesofpatientsinfectedwith2019
novelcoronavirusinWuhan,China.
Lancet(London,England)
395,497Œ506.6.SongF
etal
.(2020)Emerging2019novelcoronavirus(2019-nCoV)
pneumonia.
Radiology295,210
Œ217.7.PreventionNIfVDCa
(2020)Specificprimersandprobesfordetection
2019novelcoronavirus.Availableat
http://ivdcchinacdccn/kyjz/202001/
t20200121_211337html
.8.AssiriA
etal
.(2013)Epidemiological,demographic,andclinicalcharac-
teristicsof47casesofMiddleEastrespiratorysyndromecoronavirusdis-

easefromSaudiArabia:adescriptivestudy.
LancetInfectiousDiseases
13,752Œ761.9.KitamiA
etal
.(2012)One-dimensionalmeancomputedtomography
valueevaluationofground-glassopacityonhigh-resolutionimages.
GeneralThoracicandCardiovascularSurgery
60,425
Œ430.10.OoiGC
etal
.(2004)Severeacuterespiratorysyndrome:temporallung
changesatthin-sectionCTin30patients.
Radiology230,836
Œ844.11.WongKT
etal
.(2003)Thin-sectionCTofsevereacuterespiratorysyn-
drome:evaluationof73patientsexposedtoorwiththedisease.
Radiology228,395
Œ400.12.ChinaCPsGotPsRo
(2020)Diagnosisandtreatmentofpneumoniacaused
bySARS-CoV-2(5thtrialversion).Availableat
http://wwwgovcn/zhengce/
zhengceku/2020-02/05/content_5474791htm
.13.WangD
etal
.(2020)Clinicalcharacteristicsof138hospitalizedpatients
with2019novelcoronavirus-infectedpneumoniainWuhan,China.

JAMA323,1061
Œ1069.14.ZumlaA,HuiDSandPerlmanS
(2015)MiddleEastrespiratorysyn-
drome.
Lancet(London,England)
386,995
Œ1007.15.ArabiYM
etal
.(2014)Clinicalcourseandoutcomesofcriticallyill
patientswithMiddleEastrespiratorysyndromecoronavirusinfection.
AnnalsofInternalMedicine
160,389
Œ397.EpidemiologyandInfection
9 16.Al-TawfiqJA
etal
.(2014)MiddleEastrespiratorysyndromecoronavirus:
acase
controlstudyofhospitalizedpatients.
ClinicalInfectionDiseases
59,160
Œ165.17.AssiriA
etal
.(2013)HospitaloutbreakofMiddleEastrespiratorysyn-
dromecoronavirus.
TheNewEnglandJournalofMedicine
369,407
Œ416.18.ParkWB
etal
.(2018)Correlationbetweenpneumoniaseverityandpul-
monarycomplicationsinMiddleEastrespiratorysyndrome.
Journalof
KoreanMedicalScience
33,e169.
19.WuQ
etal
.(2017)AlteredlipidmetabolisminrecoveredSARSpatients
twelveyearsafterinfection.
ScientificReport
7,9110.
20.CohenJG
etal
.(2016)Softwareperformanceinsegmentingground-glass
andsolidcomponentsofsubsolidnodulesinpulmonaryadenocarcin-
omas.EuropeanRadiology
26,4465
Œ4474.21.ZumlaA
etal
.(2020)Reducingmortalityfrom2019-nCoV:host-directed
therapiesshouldbeanoption.
Lancet(London,England)
395,E35
ŒEE6.22.WangML
etal
.(2020)Remdesivirandchloroquineeffectivelyinhibitthe
recentlyemergednovelcoronavirus(2019-nCoV)invitro.
CellResearch
30,269
Œ271.23.LuHZ
(2020)Drugtreatmentoptionsforthe2019-newcoronavirus
(2019-nCoV).
BioscienceTrends
14,69
Œ71.10MengyaoJi
etal.
